Dr Paul Mitchell – Overview of the SCLC Treatment Landscape: the Australian Experience

These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Paul Mitchell provide an overview of the SCLC treatment landscape in Australia.

 

 

SCLC Webinar Chapters

 

Introduction: Dr Paul Mitchell

Background: Small Cell Lung Cancer

IMpower 133: Atezolizumab + Carboplatin + etoposide in 1L ES-SCLC

CASPIAN Trial: Durvalumab +Tremilimumab + etoposide in ES-SCLC

ECOG-ACRIN EA5161 – Cisplatin/carboplatin + etoposide + nivolumab in ES-SCLC

Keynote- 606. Pembrolizumab + etoposide +Cisplatin/Carboplatin in stage IV SCLC

Summary ES-SCLC: Key first-line IO trials

Checkmate 451 – Maintenance strategy of Immunotherapy

Biomarkers (PD-L1 AND TMB)

ES-SCLC: Adding Thoracic Radiotherapy and TROG Phase 2 study

 Limited Stage small cell lung cancer (LS-SCLC)

Second line options and beyond

Summary of 1^st line therapies in SCLC

Zepzelca Access Program Analysis (SCLC)

 

ZEPZELCA^® is a registered trademark of PharmaMar SA. ZEPZELCA^® is under license from PharmaMar SA.